Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $73.38 Consensus Price Target from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received an average rating of “Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $73.38.

A number of analysts recently weighed in on JSPR shares. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a report on Thursday, October 24th. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada restated an “outperform” rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research report on Monday, December 23rd. Finally, JMP Securities reiterated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, October 15th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Jasper Therapeutics in the 2nd quarter valued at about $740,000. Rhumbline Advisers bought a new stake in Jasper Therapeutics during the second quarter worth approximately $300,000. American Century Companies Inc. grew its position in Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics in the third quarter worth approximately $59,000. Finally, Fernwood Investment Management LLC increased its holdings in shares of Jasper Therapeutics by 6.9% in the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after buying an additional 3,427 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Shares of JSPR opened at $19.27 on Wednesday. Jasper Therapeutics has a 12 month low of $6.50 and a 12 month high of $31.01. The stock has a fifty day moving average price of $22.07 and a 200 day moving average price of $20.54. The company has a market cap of $289.07 million, a P/E ratio of -4.07 and a beta of 2.18.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.